Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy.
The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years...
Roche announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq...
Introduction: The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment.
Background: Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity.
Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1;...
Genentech announced data from the positive, pivotal Phase III OAK study of Tecentriq (atezolizumab) which showed Tecentriq helped people live...
Results from the FLAURA2 Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) with the addition of chemotherapy, provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) .
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
The UK National Institute for Health and Care Excellence (NICE) has recommended the use of Tecentriq (atezolizumab) from Roche to...